首页 > 最新文献

BMJ Open Gastroenterology最新文献

英文 中文
Identifying the need for a UK colorectal cancer screening programme for patients with cystic fibrosis (CF): 10-year retrospective review of colonoscopy and colorectal cancer outcomes at a single CF centre. 确定英国对囊性纤维化(CF)患者进行结直肠癌筛查计划的必要性:对单个CF中心结肠镜检查和结直肠癌结果的10年回顾性回顾。
IF 3.1 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-07-01 DOI: 10.1136/bmjgast-2023-001178
Karuna Sapru, Peter Barry, Andrew Jones, John Walmsley, Javaid Iqbal, Dipesh H Vasant

Objective: Patients with cystic fibrosis (pwCF) have a high incidence of early colorectal cancer (CRC). In the absence of a UK CRC screening programme for pwCF, we evaluated the utility and outcomes of colonoscopy and CRC at a large UK CF centre.

Design: In a retrospective study of colonoscopy and CRC outcomes between 2010 and 2020 in pwCF aged≥30 years at a large CF centre, data were collected on colonoscopy indications and findings, polyp detection rates, bowel preparation regimens and outcomes, colonoscopy completion rates, and patient outcomes.

Results: We identified 361 pwCF aged ≥30 years, of whom 135 were ≥40 years old. In the absence of a UK CRC screening guideline only 33 (9%)/361 pwCF aged ≥30 years (mean age: 44.8±11.0 years) had a colonoscopy between 2010 and 2020. Colonoscopy completion rate was 94.9%, with a 33% polyp detection rate, 93.8% of the polyps retrieved were premalignant. During the study period no patients developed postcolonoscopy CRC. However, of the patients aged ≥40 years who did not have a colonoscopy (111/135, 82.2%), four (3.6%) patients developed CRC and three pwCF died from complications of CRC.

Conclusion: In this 10-year experience from a large CF centre, colonoscopy uptake for symptomatic indications was low, yet of high yield for premalignant lesions in pwCF >40 years. These data highlight the risk of potentially preventable, early CRC, and therefore support the need for prospective, large-scale nationwide studies which may inform the need for UK CRC screening guidelines for pwCF.

目的:囊性纤维化(pwCF)患者是早期结直肠癌(CRC)的高发患者。在英国没有针对pwCF的CRC筛查项目的情况下,我们在英国一家大型CF中心评估了结肠镜检查和CRC的效用和结果。设计:在一个大型CF中心对2010年至2020年年龄≥30岁的pwCF患者结肠镜检查和结直肠癌结果进行回顾性研究,收集结肠镜检查指征和发现、息肉检出率、肠准备方案和结果、结肠镜检查完成率和患者结果的数据。结果:我们确定了361例年龄≥30岁的pwCF,其中135例年龄≥40岁。在英国没有CRC筛查指南的情况下,2010年至2020年期间,年龄≥30岁(平均年龄:44.8±11.0岁)的pwCF患者中,只有33(9%)/361人接受了结肠镜检查。结肠镜检查完成率为94.9%,息肉检出率为33%,检出息肉癌前病变率为93.8%。在研究期间,没有患者发生结肠镜检查后结直肠癌。然而,在年龄≥40岁且未进行结肠镜检查的患者中(111/135,82.2%),4例(3.6%)患者发生CRC, 3例pwCF患者死于CRC并发症。结论:在这个来自大型CF中心的10年经验中,结肠镜检查对症状适应症的使用率很低,但在>40年的pwCF中,恶性病变的发生率很高。这些数据强调了潜在可预防的早期结直肠癌的风险,因此支持了前瞻性的、大规模的全国性研究的必要性,这可能会为英国的pwCF CRC筛查指南提供信息。
{"title":"Identifying the need for a UK colorectal cancer screening programme for patients with cystic fibrosis (CF): 10-year retrospective review of colonoscopy and colorectal cancer outcomes at a single CF centre.","authors":"Karuna Sapru,&nbsp;Peter Barry,&nbsp;Andrew Jones,&nbsp;John Walmsley,&nbsp;Javaid Iqbal,&nbsp;Dipesh H Vasant","doi":"10.1136/bmjgast-2023-001178","DOIUrl":"https://doi.org/10.1136/bmjgast-2023-001178","url":null,"abstract":"<p><strong>Objective: </strong>Patients with cystic fibrosis (pwCF) have a high incidence of early colorectal cancer (CRC). In the absence of a UK CRC screening programme for pwCF, we evaluated the utility and outcomes of colonoscopy and CRC at a large UK CF centre.</p><p><strong>Design: </strong>In a retrospective study of colonoscopy and CRC outcomes between 2010 and 2020 in pwCF aged≥30 years at a large CF centre, data were collected on colonoscopy indications and findings, polyp detection rates, bowel preparation regimens and outcomes, colonoscopy completion rates, and patient outcomes.</p><p><strong>Results: </strong>We identified 361 pwCF aged ≥30 years, of whom 135 were ≥40 years old. In the absence of a UK CRC screening guideline only 33 (9%)/361 pwCF aged ≥30 years (mean age: 44.8±11.0 years) had a colonoscopy between 2010 and 2020. Colonoscopy completion rate was 94.9%, with a 33% polyp detection rate, 93.8% of the polyps retrieved were premalignant. During the study period no patients developed postcolonoscopy CRC. However, of the patients aged ≥40 years who did not have a colonoscopy (111/135, 82.2%), four (3.6%) patients developed CRC and three pwCF died from complications of CRC.</p><p><strong>Conclusion: </strong>In this 10-year experience from a large CF centre, colonoscopy uptake for symptomatic indications was low, yet of high yield for premalignant lesions in pwCF >40 years. These data highlight the risk of potentially preventable, early CRC, and therefore support the need for prospective, large-scale nationwide studies which may inform the need for UK CRC screening guidelines for pwCF.</p>","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":"10 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391801/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9994477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence and trends of transfusion transmissible infections among blood donors in Basra, Iraq. 伊拉克巴士拉献血者中输血传播感染的流行和趋势。
IF 3.1 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-07-01 DOI: 10.1136/bmjgast-2022-000968
Khairallah A S Mohammed, Maha M Hameed, Abdullah H Mousa, Amar T Saleh

Background: Despite saving millions of lives through blood transfusion, transfusion-transmissible infections (TTIs) still threaten the lives of patients requiring blood transfusion. Hence, screening blood donors and studying the prevalence of TTIs among blood donors may display the burden of these diseases among our population. The aim of this study was to assess the seroprevalence rates of transfusion transmitted infections among blood donors in Basra, Iraq from 2019 to 2021 as groundwork for providing safe blood transfusion in Iraq.

Methods: A cross-sectional study was carried out in the blood banks in Basra, Iraq from 1 January 2019 to 31 December 2021. A total of 197 898 samples were collected and screened for hepatitis B surface antigen (HBsAg), anti-hepatitis B core (HBc), anti-hepatitis C virus (HCV) and syphilis immunologically.

Results: The prevalence rates of seropositive of viral hepatitis for the year 2019, 2020, 2021 were as following: hepatitis B virus (HBV) rates 1.54%, 1.45% and 1.14% with significant declined trend by 26%; anti-HCV rates were 0.14, 0.12 and 0.11% with significant declined trend by 21.4%; and the syphilis rates were 0.38, 0.47, 0.36 with marked declined trend 5.3%, respectively.Of those donors showed HBV positive, 2503 (1.26%) had positive anti-HBc results, while only 173 (0.0874) showed positive test results for both anti-HBc and HBsAg.

Conclusion: Prevalence rates of viral hepatitis and syphilis showed a steady decline between 2019 and 2021, and these rates were much lower in Basra than in other parts of Iraq and neighbouring countries. The importance of using the anti-HBc test in the screening of blood donors was indicated in this study. These findings would contribute in improving the understanding of TTIs epidemiology and supporting health authorities controlling bloodborne diseases.

背景:尽管输血挽救了数百万人的生命,但输血传播感染(tti)仍然威胁着需要输血的患者的生命。因此,对献血者进行筛查并研究献血者中感染性传播疾病的流行情况,可能会显示出这些疾病在我国人口中的负担。本研究的目的是评估2019年至2021年伊拉克巴士拉献血者中输血传播感染的血清患病率,作为在伊拉克提供安全输血的基础。方法:2019年1月1日至2021年12月31日在伊拉克巴士拉血库进行横断面研究。采集样本197 898份,进行乙型肝炎表面抗原(HBsAg)、抗乙型肝炎核心病毒(HBc)、抗丙型肝炎病毒(HCV)和梅毒免疫筛查。结果:2019年、2020年、2021年病毒性肝炎血清阳性率分别为:乙型肝炎病毒(HBV)阳性率1.54%、1.45%、1.14%,呈明显下降趋势,分别下降26%;抗- hcv阳性率分别为0.14%、0.12%和0.11%,呈显著下降趋势,降幅为21.4%;梅毒感染率分别为0.38、0.47、0.36,呈明显下降趋势,降幅为5.3%。在HBV阳性献血者中,抗hbc阳性2503例(1.26%),抗hbc和HBsAg均阳性173例(0.0874)。结论:病毒性肝炎和梅毒的患病率在2019年至2021年期间呈稳步下降趋势,巴士拉的患病率远低于伊拉克其他地区和邻国。本研究表明,在筛选献血者时使用抗hbc检测的重要性。这些发现将有助于提高对tti流行病学的了解,并支持卫生当局控制血源性疾病。
{"title":"Prevalence and trends of transfusion transmissible infections among blood donors in Basra, Iraq.","authors":"Khairallah A S Mohammed,&nbsp;Maha M Hameed,&nbsp;Abdullah H Mousa,&nbsp;Amar T Saleh","doi":"10.1136/bmjgast-2022-000968","DOIUrl":"https://doi.org/10.1136/bmjgast-2022-000968","url":null,"abstract":"<p><strong>Background: </strong>Despite saving millions of lives through blood transfusion, transfusion-transmissible infections (TTIs) still threaten the lives of patients requiring blood transfusion. Hence, screening blood donors and studying the prevalence of TTIs among blood donors may display the burden of these diseases among our population. The aim of this study was to assess the seroprevalence rates of transfusion transmitted infections among blood donors in Basra, Iraq from 2019 to 2021 as groundwork for providing safe blood transfusion in Iraq.</p><p><strong>Methods: </strong>A cross-sectional study was carried out in the blood banks in Basra, Iraq from 1 January 2019 to 31 December 2021. A total of 197 898 samples were collected and screened for hepatitis B surface antigen (HBsAg), anti-hepatitis B core (HBc), anti-hepatitis C virus (HCV) and syphilis immunologically.</p><p><strong>Results: </strong>The prevalence rates of seropositive of viral hepatitis for the year 2019, 2020, 2021 were as following: hepatitis B virus (HBV) rates 1.54%, 1.45% and 1.14% with significant declined trend by 26%; anti-HCV rates were 0.14, 0.12 and 0.11% with significant declined trend by 21.4%; and the syphilis rates were 0.38, 0.47, 0.36 with marked declined trend 5.3%, respectively.Of those donors showed HBV positive, 2503 (1.26%) had positive anti-HBc results, while only 173 (0.0874) showed positive test results for both anti-HBc and HBsAg.</p><p><strong>Conclusion: </strong>Prevalence rates of viral hepatitis and syphilis showed a steady decline between 2019 and 2021, and these rates were much lower in Basra than in other parts of Iraq and neighbouring countries. The importance of using the anti-HBc test in the screening of blood donors was indicated in this study. These findings would contribute in improving the understanding of TTIs epidemiology and supporting health authorities controlling bloodborne diseases.</p>","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":"10 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/99/b1/bmjgast-2022-000968.PMC10373717.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9940655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Variation in the rate of detection of minute and small early gastric cancers at diagnostic endoscopy may reflect the performance of individual endoscopists. 在诊断性内窥镜检查中微小和早期胃癌的检出率的差异可能反映了个体内窥镜医生的表现。
IF 3.1 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-07-01 DOI: 10.1136/bmjgast-2023-001143
Daisuke Murakami, Masayuki Yamato, Yuji Amano, Takayoshi Nishino, Makoto Arai

Objective: The documented variation in gastric cancer (GC) detection among endoscopists has often been dismissed as a coincidental artefact of the low incidence of gastric neoplasms; it is not considered associated with differences in physicians' performance of the esophagogastroduodenoscopy procedure. This study is to confirm whether significant variations among endoscopists in early GC detection suggest the individual performance of the upper endoscopy.

Design: A retrospective observational study at a single centre in Japan assessed the results of 218 early GCs detected during 25 688 routine esophagogastroduodenoscopies by 12 endoscopists. The main outcome was the rate of early GC detection for each endoscopist under the same circumstances. Other measures included the major diameters and locations of the lesions, Helicobacter pylori infection status, and baseline patient characteristics that could affect the prevalence of GC.

Results: The early GC detection rates exhibited wide variation among endoscopists (0.09%-2.87%) despite performing routine esophagogastroduodenoscopies in a population with a similar background. Endoscopists were assigned to a low-detection group (n=6; detection rate: 0.47% (range: 0.09%-0.55%)) and a high-detection group (n=5; detection rate: 0.83% (range: 0.63%-1.12%)), with the single highest detector analysed separately due to his distinct detection rate (2.87%). Endoscopists in the high-detection group had better detection rates for minute (major diameter ≤5 mm) and small (major diameter 6-10 mm) GCs than the low-detection group (0.19%/0.23% vs 0.085%/0.098%). These differences were significant (p<0.01), although there were no significant differences in detection of larger tumours (major diameter ≥11 mm; 0.40% vs 0.28%; p=0.13). The tumour location and H. pylori status were similar in the low-detection group, high-detection group and for the highest detector.

Conclusion: Significant variation in the detection of hard-to-find, smaller GCs may reflect individual performance of the examination.

目的:内镜医师在胃癌(GC)检测上的差异常常被认为是胃肿瘤低发病率的巧合;它不被认为与医生在食管胃十二指肠镜检查过程中的表现差异有关。本研究旨在证实内镜医师在早期GC检测中的显著差异是否表明上消化道内镜的个体表现。设计:日本单一中心的回顾性观察研究评估了12名内镜医师在25688例常规食管胃十二指肠镜检查中检测到的218例早期GCs的结果。主要结果是在相同情况下每个内镜医师的早期GC检出率。其他措施包括病变的主要直径和位置,幽门螺杆菌感染状况,以及可能影响GC患病率的基线患者特征。结果:尽管在背景相似的人群中进行常规食管胃十二指肠镜检查,但内镜医师之间的早期GC检出率差异很大(0.09%-2.87%)。内窥镜医师被分配到低检出率组(n=6;检出率:0.47%(范围:0.09% ~ 0.55%),高检出率组(n=5;检出率:0.83%(范围:0.63% ~ 1.12%),检出率较高的单一检出率较高(2.87%),单独分析。高检出率组对微小(大径≤5 mm)和微小(大径6 ~ 10 mm)胃癌的检出率高于低检出率组(0.19%/0.23% vs 0.085%/0.098%)。这些差异是显著的(pH.幽门螺杆菌状态在低检出率组、高检出率组和最高检出率组相似)。结论:难以发现的、较小的gc在检测上的显著差异可能反映了检查的个人表现。
{"title":"Variation in the rate of detection of minute and small early gastric cancers at diagnostic endoscopy may reflect the performance of individual endoscopists.","authors":"Daisuke Murakami,&nbsp;Masayuki Yamato,&nbsp;Yuji Amano,&nbsp;Takayoshi Nishino,&nbsp;Makoto Arai","doi":"10.1136/bmjgast-2023-001143","DOIUrl":"https://doi.org/10.1136/bmjgast-2023-001143","url":null,"abstract":"<p><strong>Objective: </strong>The documented variation in gastric cancer (GC) detection among endoscopists has often been dismissed as a coincidental artefact of the low incidence of gastric neoplasms; it is not considered associated with differences in physicians' performance of the esophagogastroduodenoscopy procedure. This study is to confirm whether significant variations among endoscopists in early GC detection suggest the individual performance of the upper endoscopy.</p><p><strong>Design: </strong>A retrospective observational study at a single centre in Japan assessed the results of 218 early GCs detected during 25 688 routine esophagogastroduodenoscopies by 12 endoscopists. The main outcome was the rate of early GC detection for each endoscopist under the same circumstances. Other measures included the major diameters and locations of the lesions, <i>Helicobacter pylori</i> infection status, and baseline patient characteristics that could affect the prevalence of GC.</p><p><strong>Results: </strong>The early GC detection rates exhibited wide variation among endoscopists (0.09%-2.87%) despite performing routine esophagogastroduodenoscopies in a population with a similar background. Endoscopists were assigned to a low-detection group (n=6; detection rate: 0.47% (range: 0.09%-0.55%)) and a high-detection group (n=5; detection rate: 0.83% (range: 0.63%-1.12%)), with the single highest detector analysed separately due to his distinct detection rate (2.87%). Endoscopists in the high-detection group had better detection rates for minute (major diameter ≤5 mm) and small (major diameter 6-10 mm) GCs than the low-detection group (0.19%/0.23% vs 0.085%/0.098%). These differences were significant (p<0.01), although there were no significant differences in detection of larger tumours (major diameter ≥11 mm; 0.40% vs 0.28%; p=0.13). The tumour location and <i>H. pylori</i> status were similar in the low-detection group, high-detection group and for the highest detector.</p><p><strong>Conclusion: </strong>Significant variation in the detection of hard-to-find, smaller GCs may reflect individual performance of the examination.</p>","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":"10 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fc/65/bmjgast-2023-001143.PMC10335432.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10201117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Toll-like receptor 5 tunes hepatic and pancreatic stellate cells activation. toll样受体5调节肝脏和胰腺星状细胞的激活。
IF 3.1 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-07-01 DOI: 10.1136/bmjgast-2023-001148
Pietro Di Fazio, Sophia Mielke, Isabell T Böhm, Malte Buchholz, Sami Matrood, Detlef Schuppan, Thaddeus Wissniowski

Objective: Stellate cells are responsible for liver and pancreas fibrosis and strictly correlate with tumourigenesis. Although their activation is reversible, an exacerbated signalling triggers chronic fibrosis. Toll-like receptors (TLRs) modulate stellate cells transition. TLR5 transduces the signal deriving by the binding to bacterial flagellin from invading mobile bacteria.

Design: Human hepatic and pancreatic stellate cells were activated by the administration of transforming growth factor-beta (TGF-β). TLR5 was transiently knocked down by short-interference RNA transfection. Reverse Transcription-quantitativePCR and western blot were performed to analyse the transcript and protein level of TLR5 and the transition players. Fluorescence microscopy was performed to identify these targets in spheroids and in the sections of murine fibrotic liver.

Results: TGF-β-activated human hepatic and pancreatic stellate cells showed an increase of TLR5 expression. TLR5 knockdown blocked the activation of those stellate cells. Furthermore, TLR5 busted during murine liver fibrosis and co-localised with the inducible Collagen I. Flagellin suppressed TLR5, COL1A1 and ACTA2 expression after the administration of TGF-β. Instead, the antagonist of TLR5 did not block the effect of TGF-β. Wortmannin, a specific AKT inhibitor, induced TLR5 but not COL1A1 and ACTA2 transcript and protein level.

Conclusion: TGF-β-mediated activation of hepatic and pancreatic stellate cells requires the over-expression of TLR5. Instead, its autonomous signalling inhibits the activation of the stellate cells, thus prompting a signalling through different regulatory pathways.

目的:星状细胞与肝、胰腺纤维化有关,与肿瘤发生密切相关。尽管它们的激活是可逆的,但信号加剧会引发慢性纤维化。toll样受体(TLRs)调节星状细胞的转变。TLR5转导入侵的移动细菌与细菌鞭毛蛋白结合产生的信号。设计:通过转化生长因子-β (TGF-β)激活人肝脏和胰腺星状细胞。短干扰RNA转染可短暂敲低TLR5。采用逆转录-定量pcr和western blot方法分析TLR5及其过渡基因的转录和蛋白水平。荧光显微镜在小鼠纤维化肝的球体和切片中鉴定这些靶标。结果:TGF-β激活的人肝、胰星状细胞TLR5表达升高。TLR5敲低阻断了这些星状细胞的激活。此外,TLR5在小鼠肝纤维化过程中被破坏,并与诱导型胶原共定位。鞭毛蛋白在给药TGF-β后抑制TLR5、COL1A1和ACTA2的表达。相反,TLR5拮抗剂不能阻断TGF-β的作用。Wortmannin是一种特异性AKT抑制剂,可诱导TLR5,但不影响COL1A1和ACTA2的转录和蛋白水平。结论:TGF-β介导的肝、胰腺星状细胞活化需要TLR5过表达。相反,它的自主信号抑制星状细胞的激活,从而促使信号通过不同的调节途径。
{"title":"Toll-like receptor 5 tunes hepatic and pancreatic stellate cells activation.","authors":"Pietro Di Fazio,&nbsp;Sophia Mielke,&nbsp;Isabell T Böhm,&nbsp;Malte Buchholz,&nbsp;Sami Matrood,&nbsp;Detlef Schuppan,&nbsp;Thaddeus Wissniowski","doi":"10.1136/bmjgast-2023-001148","DOIUrl":"https://doi.org/10.1136/bmjgast-2023-001148","url":null,"abstract":"<p><strong>Objective: </strong>Stellate cells are responsible for liver and pancreas fibrosis and strictly correlate with tumourigenesis. Although their activation is reversible, an exacerbated signalling triggers chronic fibrosis. Toll-like receptors (TLRs) modulate stellate cells transition. TLR5 transduces the signal deriving by the binding to bacterial flagellin from invading mobile bacteria.</p><p><strong>Design: </strong>Human hepatic and pancreatic stellate cells were activated by the administration of transforming growth factor-beta (TGF-β). TLR5 was transiently knocked down by short-interference RNA transfection. Reverse Transcription-quantitativePCR and western blot were performed to analyse the transcript and protein level of TLR5 and the transition players. Fluorescence microscopy was performed to identify these targets in spheroids and in the sections of murine fibrotic liver.</p><p><strong>Results: </strong>TGF-β-activated human hepatic and pancreatic stellate cells showed an increase of <i>TLR5</i> expression. <i>TLR5</i> knockdown blocked the activation of those stellate cells. Furthermore, TLR5 busted during murine liver fibrosis and co-localised with the inducible Collagen I. Flagellin suppressed <i>TLR5</i>, <i>COL1A1</i> and <i>ACTA2</i> expression after the administration of TGF-β. Instead, the antagonist of TLR5 did not block the effect of TGF-β. Wortmannin, a specific AKT inhibitor, induced <i>TLR5</i> but not <i>COL1A1</i> and <i>ACTA2</i> transcript and protein level.</p><p><strong>Conclusion: </strong>TGF-β-mediated activation of hepatic and pancreatic stellate cells requires the over-expression of TLR5. Instead, its autonomous signalling inhibits the activation of the stellate cells, thus prompting a signalling through different regulatory pathways.</p>","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":"10 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/00/0f/bmjgast-2023-001148.PMC10347502.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9846484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effectiveness of using a patient education mobile application to improve the quality of bowel preparation: a randomised controlled trial. 使用患者教育移动应用程序提高肠道准备质量的有效性:一项随机对照试验。
IF 3.1 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-06-01 DOI: 10.1136/bmjgast-2023-001107
Hang Viet Dao, Quan Viet Dao, Hoa Ngoc Lam, Long Bao Hoang, Van Thi Nguyen, Thuy Thi Nguyen, Dat Quoc Vu, Christopher S Pokorny, Hoa Lan Nguyen, Jeroan Allison, Robert Joel Goldberg, An Thi Minh Dao, Toan Thanh Thi Do, Long Van Dao

Aims: To determine the effectiveness of a mobile application (app) in improving the quality of bowel preparation for colonoscopy.

Method: An endoscopist-blinded randomised controlled trial enrolled patients who were undergoing a colonoscopy on the same day of bowel preparation. The intervention used a Vietnamese mobile app that provides instructions on bowel preparation while patients in the comparison group received conventional instructions. Outcomes included the Boston Bowel Preparation Scale (BBPS) to assess the quality of bowel preparation and the polyp detection rate (PDR) and adenoma detection rate (ADR).

Results: The study recruited 515 patients (256 in the intervention group). The median age was 42 years, 50.9% were females, 69.1% high school graduates and higher, and 45.2% from urban area. Patients in the intervention group had higher adherence to instructions (60.9% vs 52.4%, p=0.05) and longer length of taking laxatives (mean difference 0.17 hours, 95% CI 0.06 to 0.27). The intervention did not reduce the risk of poor bowel cleansing (total BBPS<6) in both overall (7.4% vs 7.7%; risk ratio 0.96, 95% CI 0.53 to 1.76) and subgroup analysis. PDR and ADR were similar between the two groups.

Conclusions: The mobile app providing instructions on proper bowel preparation improved the practice during bowel preparation but did not improve the quality of bowel cleansing or PDR.

目的:确定移动应用程序(app)在提高结肠镜检查肠道准备质量方面的有效性。方法:一项内镜盲法随机对照试验纳入了在肠准备当天进行结肠镜检查的患者。干预使用越南移动应用程序,该应用程序提供肠道准备指导,而对照组患者则接受常规指导。结果包括波士顿肠准备量表(BBPS)评估肠准备质量、息肉检出率(PDR)和腺瘤检出率(ADR)。结果:共纳入515例患者(干预组256例)。年龄中位数为42岁,女性占50.9%,高中及以上学历占69.1%,城镇人口占45.2%。干预组患者对医嘱的依从性更高(60.9% vs 52.4%, p=0.05),服用泻药的时间更长(平均差异0.17小时,95% CI 0.06 ~ 0.27)。干预并没有降低排便不良的风险(总bbps)。结论:提供适当排便指导的移动应用程序改善了排便过程中的做法,但没有提高排便或PDR的质量。
{"title":"Effectiveness of using a patient education mobile application to improve the quality of bowel preparation: a randomised controlled trial.","authors":"Hang Viet Dao,&nbsp;Quan Viet Dao,&nbsp;Hoa Ngoc Lam,&nbsp;Long Bao Hoang,&nbsp;Van Thi Nguyen,&nbsp;Thuy Thi Nguyen,&nbsp;Dat Quoc Vu,&nbsp;Christopher S Pokorny,&nbsp;Hoa Lan Nguyen,&nbsp;Jeroan Allison,&nbsp;Robert Joel Goldberg,&nbsp;An Thi Minh Dao,&nbsp;Toan Thanh Thi Do,&nbsp;Long Van Dao","doi":"10.1136/bmjgast-2023-001107","DOIUrl":"https://doi.org/10.1136/bmjgast-2023-001107","url":null,"abstract":"<p><strong>Aims: </strong>To determine the effectiveness of a mobile application (app) in improving the quality of bowel preparation for colonoscopy.</p><p><strong>Method: </strong>An endoscopist-blinded randomised controlled trial enrolled patients who were undergoing a colonoscopy on the same day of bowel preparation. The intervention used a Vietnamese mobile app that provides instructions on bowel preparation while patients in the comparison group received conventional instructions. Outcomes included the Boston Bowel Preparation Scale (BBPS) to assess the quality of bowel preparation and the polyp detection rate (PDR) and adenoma detection rate (ADR).</p><p><strong>Results: </strong>The study recruited 515 patients (256 in the intervention group). The median age was 42 years, 50.9% were females, 69.1% high school graduates and higher, and 45.2% from urban area. Patients in the intervention group had higher adherence to instructions (60.9% vs 52.4%, p=0.05) and longer length of taking laxatives (mean difference 0.17 hours, 95% CI 0.06 to 0.27). The intervention did not reduce the risk of poor bowel cleansing (total BBPS<6) in both overall (7.4% vs 7.7%; risk ratio 0.96, 95% CI 0.53 to 1.76) and subgroup analysis. PDR and ADR were similar between the two groups.</p><p><strong>Conclusions: </strong>The mobile app providing instructions on proper bowel preparation improved the practice during bowel preparation but did not improve the quality of bowel cleansing or PDR.</p>","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":"10 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ee/a8/bmjgast-2023-001107.PMC10255132.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9682799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
EUS-guided through the needle microbiopsy: a useful adjunct in the investigation of pancreatic cystic lesions. eus引导下的针显微活检:胰腺囊性病变的一种有用的辅助检查。
IF 3.1 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-06-01 DOI: 10.1136/bmjgast-2023-001184
Wafaa Ahmed, Mikaeil Mirzaali, Caroline Young, Latifu Sanni, Simon Everett, Bharat Paranandi, Matthew T Huggett, Wei On

Objective: Endoscopic ultrasound-guided through-the-needle microbiopsy (EUS-TTNB) forceps is a recent development that facilitates sampling of the walls of pancreatic cystic lesions (PCL) for histological analysis. We aimed to assess the impact of EUS-TTNB and its influence on patient management in a tertiary pancreas centre.

Design: A prospective database of consecutive patients who underwent EUS-TTNB from March 2020 to August 2022 at a tertiary referral centre was retrospectively analysed.

Results: Thirty-four patients (22 women) were identified. Technical success was achieved in all cases. Adequate specimens for histological diagnosis were obtained in 25 (74%) cases. Overall, EUS-TTNB led to a change in management in 24 (71%) cases. Sixteen (47%) patients were downstaged, with 5 (15%) discharged from surveillance. Eight (24%) were upstaged, with 5 (15%) referred for surgical resection. In the 10 (29%) cases without change in management, 7 (21%) had confirmation of diagnosis with no change in surveillance, and 3 (9%) had insufficient biopsies on EUS-TTNB. Two (6%) patients developed post-procedural pancreatitis, and 1 (3%) developed peri-procedural intracystic bleeding with no subsequent clinical sequelae.

Conclusion: EUS-TTNB permits histological confirmation of the nature of PCL, which can alter management outcomes. Care should be taken in patient selection and appropriately consented due to the adverse event rate.

目的:超声内镜引导下穿刺显微活检(EUS-TTNB)钳是最近的一项发展,有助于胰腺囊性病变(PCL)壁取样进行组织学分析。我们的目的是评估EUS-TTNB的影响及其对三级胰腺中心患者管理的影响。设计:回顾性分析2020年3月至2022年8月在三级转诊中心连续接受EUS-TTNB患者的前瞻性数据库。结果:34例患者(22例女性)被确诊。在所有情况下都取得了技术上的成功。25例(74%)病例获得足够的组织学诊断标本。总体而言,EUS-TTNB导致24例(71%)病例的管理改变。16例(47%)患者降级,5例(15%)患者退出监测。8例(24%)被抢镜,5例(15%)被转介手术切除。在10例(29%)未改变治疗的病例中,7例(21%)确诊,监测未改变,3例(9%)EUS-TTNB活检不充分。2例(6%)患者出现手术后胰腺炎,1例(3%)患者出现术中囊内出血,无后续临床后遗症。结论:EUS-TTNB允许组织学确认PCL的性质,这可以改变治疗结果。由于不良事件发生率,在患者选择和适当同意时应谨慎。
{"title":"EUS-guided through the needle microbiopsy: a useful adjunct in the investigation of pancreatic cystic lesions.","authors":"Wafaa Ahmed,&nbsp;Mikaeil Mirzaali,&nbsp;Caroline Young,&nbsp;Latifu Sanni,&nbsp;Simon Everett,&nbsp;Bharat Paranandi,&nbsp;Matthew T Huggett,&nbsp;Wei On","doi":"10.1136/bmjgast-2023-001184","DOIUrl":"https://doi.org/10.1136/bmjgast-2023-001184","url":null,"abstract":"<p><strong>Objective: </strong>Endoscopic ultrasound-guided through-the-needle microbiopsy (EUS-TTNB) forceps is a recent development that facilitates sampling of the walls of pancreatic cystic lesions (PCL) for histological analysis. We aimed to assess the impact of EUS-TTNB and its influence on patient management in a tertiary pancreas centre.</p><p><strong>Design: </strong>A prospective database of consecutive patients who underwent EUS-TTNB from March 2020 to August 2022 at a tertiary referral centre was retrospectively analysed.</p><p><strong>Results: </strong>Thirty-four patients (22 women) were identified. Technical success was achieved in all cases. Adequate specimens for histological diagnosis were obtained in 25 (74%) cases. Overall, EUS-TTNB led to a change in management in 24 (71%) cases. Sixteen (47%) patients were downstaged, with 5 (15%) discharged from surveillance. Eight (24%) were upstaged, with 5 (15%) referred for surgical resection. In the 10 (29%) cases without change in management, 7 (21%) had confirmation of diagnosis with no change in surveillance, and 3 (9%) had insufficient biopsies on EUS-TTNB. Two (6%) patients developed post-procedural pancreatitis, and 1 (3%) developed peri-procedural intracystic bleeding with no subsequent clinical sequelae.</p><p><strong>Conclusion: </strong>EUS-TTNB permits histological confirmation of the nature of PCL, which can alter management outcomes. Care should be taken in patient selection and appropriately consented due to the adverse event rate.</p>","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":"10 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f6/b6/bmjgast-2023-001184.PMC10314575.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9840824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Randomised controlled trials of non-pharmacological interventions to improve patient-reported outcomes of colonoscopy: a scoping review. 非药物干预改善患者结肠镜检查结果的随机对照试验:范围回顾。
IF 3.1 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-06-01 DOI: 10.1136/bmjgast-2023-001129
Colin Sue-Chue-Lam, Matthew Castelo, Amina Benmessaoud, Teruko Kishibe, Diego Llovet, Christine Brezden-Masley, Amy Yx Yu, Jill Tinmouth, Nancy N Baxter

Background and aims: Non-pharmacological interventions to improve patient-reported outcomes of colonoscopy may be effective at mitigating negative experiences and perceptions of the procedure, but research to characterise the extent and features of studies of these interventions is limited.

Methods: We conducted a scoping review searching multiple databases for peer-reviewed publications of randomised controlled trials conducted in adults investigating a non-pharmacological intervention to improve patient-reported outcomes of colonoscopy. Study characteristics were tabulated and summarised narratively and graphically.

Results: We screened 5939 citations and 962 full texts, and included 245 publications from 39 countries published between 1992 and 2022. Of these, 80.8% were full publications and 19.2% were abstracts. Of the 41.9% of studies reporting funding sources, 11.4% were unfunded. The most common interventions were carbon dioxide and/or water insufflation methods (33.9%), complementary and alternative medicines (eg, acupuncture) (20.0%), and colonoscope technology (eg, magnetic scope guide) (21.6%). Pain was as an outcome across 82.0% of studies. Studies most often used a patient-reported outcome examining patient experience during the procedure (60.0%), but 42.9% of studies included an outcome without specifying the time that the patient experienced the outcome. Most intraprocedural patient-reported outcomes were measured retrospectively rather than contemporaneously, although studies varied in terms of when outcomes were assessed.

Conclusion: Research on non-pharmacological interventions to improve patient-reported outcomes of colonoscopy is unevenly distributed across types of intervention and features high variation in study design and reporting, in particular around outcomes. Future research efforts into non-pharmacological interventions to improve patient-reported outcomes of colonoscopy should be directed at underinvestigated interventions and developing consensus-based guidelines for study design, with particular attention to how and when outcomes are experienced and measured.

Prospero registration number: 42020173906.

背景和目的:改善患者报告的结肠镜检查结果的非药物干预可能有效地减轻对该手术的负面体验和看法,但对这些干预研究的程度和特征的研究是有限的。方法:我们进行了一项范围综述,在多个数据库中检索同行评议的随机对照试验的出版物,这些试验在成人中进行,研究非药物干预以改善患者报告的结肠镜检查结果。将研究特征制成表格,并以叙述和图形方式进行总结。结果:我们筛选了5939篇引文和962篇全文,包括了1992年至2022年间出版的来自39个国家的245篇出版物。其中80.8%为全文,19.2%为摘要。在报告资金来源的41.9%的研究中,11.4%没有得到资助。最常见的干预措施是二氧化碳和/或水注入法(33.9%),补充和替代药物(如针灸)(20.0%)和结肠镜技术(如磁力镜引导)(21.6%)。在82.0%的研究中,疼痛被作为结果。研究最常使用患者报告的结果来检查患者在手术过程中的经历(60.0%),但42.9%的研究包括没有指定患者经历结果的时间的结果。大多数术中患者报告的结果是回顾性测量的,而不是同时测量的,尽管研究在评估结果的时间方面有所不同。结论:改善结肠镜检查患者报告结果的非药物干预研究在不同类型的干预中分布不均匀,研究设计和报告的差异很大,特别是在结果方面。未来对改善患者结肠镜检查结果的非药物干预措施的研究应针对未充分调查的干预措施,并制定基于共识的研究设计指南,特别注意如何以及何时体验和测量结果。普洛斯彼罗注册号:42020173906。
{"title":"Randomised controlled trials of non-pharmacological interventions to improve patient-reported outcomes of colonoscopy: a scoping review.","authors":"Colin Sue-Chue-Lam,&nbsp;Matthew Castelo,&nbsp;Amina Benmessaoud,&nbsp;Teruko Kishibe,&nbsp;Diego Llovet,&nbsp;Christine Brezden-Masley,&nbsp;Amy Yx Yu,&nbsp;Jill Tinmouth,&nbsp;Nancy N Baxter","doi":"10.1136/bmjgast-2023-001129","DOIUrl":"https://doi.org/10.1136/bmjgast-2023-001129","url":null,"abstract":"<p><strong>Background and aims: </strong>Non-pharmacological interventions to improve patient-reported outcomes of colonoscopy may be effective at mitigating negative experiences and perceptions of the procedure, but research to characterise the extent and features of studies of these interventions is limited.</p><p><strong>Methods: </strong>We conducted a scoping review searching multiple databases for peer-reviewed publications of randomised controlled trials conducted in adults investigating a non-pharmacological intervention to improve patient-reported outcomes of colonoscopy. Study characteristics were tabulated and summarised narratively and graphically.</p><p><strong>Results: </strong>We screened 5939 citations and 962 full texts, and included 245 publications from 39 countries published between 1992 and 2022. Of these, 80.8% were full publications and 19.2% were abstracts. Of the 41.9% of studies reporting funding sources, 11.4% were unfunded. The most common interventions were carbon dioxide and/or water insufflation methods (33.9%), complementary and alternative medicines (eg, acupuncture) (20.0%), and colonoscope technology (eg, magnetic scope guide) (21.6%). Pain was as an outcome across 82.0% of studies. Studies most often used a patient-reported outcome examining patient experience during the procedure (60.0%), but 42.9% of studies included an outcome without specifying the time that the patient experienced the outcome. Most intraprocedural patient-reported outcomes were measured retrospectively rather than contemporaneously, although studies varied in terms of when outcomes were assessed.</p><p><strong>Conclusion: </strong>Research on non-pharmacological interventions to improve patient-reported outcomes of colonoscopy is unevenly distributed across types of intervention and features high variation in study design and reporting, in particular around outcomes. Future research efforts into non-pharmacological interventions to improve patient-reported outcomes of colonoscopy should be directed at underinvestigated interventions and developing consensus-based guidelines for study design, with particular attention to how and when outcomes are experienced and measured.</p><p><strong>Prospero registration number: </strong>42020173906.</p>","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":"10 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/02/03/bmjgast-2023-001129.PMC10255139.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9682800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between 6-thioguanine nucleotide levels and preventing production of antibodies to infliximab in patients with inflammatory bowel disease. 炎症性肠病患者6-硫鸟嘌呤核苷酸水平与预防英夫利昔单抗抗体产生之间的关系
IF 3.1 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-06-01 DOI: 10.1136/bmjgast-2023-001149
Jennifer Phillips, Sam Leary, Jonathan Tyrrell-Price

Objective: Combination therapy with infliximab and a thiopurine has been shown to be more effective than monotherapy in patients with inflammatory bowel disease (IBD). The therapeutic efficacy of thiopurines is correlated with 6-thioguanine (6-TGN) levels between 235 and 450 pmol/8×108 erythrocytes. The primary aim of the study was to investigate the association between 6-TGN levels and inhibition prevention of the production of antibodies to infliximab (ATI).

Design: We performed a retrospective review of the medical records of patients being treated with infliximab for IBD at University Hospitals Bristol NHS Foundation Trust. Demographic and biochemical data were extracted, alongside thiopurine metabolite levels, trough levels of infliximab and the presence of ATI. χ2 tests were used to investigate the association between 6-TGN levels and prevention of ATI. Logistic regression was used to compare the odds of prevented ATI between those with a 6-TGN level between 235 and 450 pmol/8×108 erythrocytes, those with a 6-TGN level outside of this range, and the baseline group who were on infliximab monotherapy.

Results: Data were extracted for 100 patients. Six of 32 patients with a 6-TGN level between 235 and 450 pmol/8×108 erythrocytes developed ATI (18.8%) compared with 14 out of 22 (63.6%) patients with a 6-TGN outside of this range and 32 out of 46 (69.6%) patients on monotherapy (p=0.001). The OR (95% CI) for prevented ATI in those with a 6-TGN between 235 and 450 pmol/8×108 erythrocytes compared with a 6-TGN outside of this range was 7.6 (2.2, 26.3) (p=0.001) and compared with monotherapy was 9.9 (3.3, 29.4) (p=0.001).

Conclusion: 6-TGN levels between 235 and 450 pmol/8×108 erythrocytes prevented production of ATI. This supports therapeutic drug monitoring to help guide treatment and maximise the beneficial effects of combination therapy for patients with IBD.

目的:英夫利昔单抗和硫嘌呤联合治疗炎症性肠病(IBD)患者已被证明比单药治疗更有效。硫嘌呤的治疗效果与6-硫鸟嘌呤(6-TGN)水平在235 ~ 450 pmol/8×108红细胞之间相关。该研究的主要目的是研究6-TGN水平与抑制预防英夫利昔单抗(ATI)抗体产生之间的关系。设计:我们对布里斯托大学医院NHS基金会信托接受英夫利昔单抗治疗IBD患者的医疗记录进行了回顾性审查。提取了人口统计学和生化数据,以及硫嘌呤代谢物水平、英夫利昔单抗低谷水平和ATI的存在。采用χ2检验探讨6-TGN水平与ATI预防之间的关系。采用Logistic回归比较6-TGN水平在235 - 450 pmol/8×108之间的红细胞、6-TGN水平在此范围之外的红细胞和接受英夫利昔单抗单药治疗的基线组预防ATI的几率。结果:共提取100例患者资料。32例6-TGN水平在235 - 450 pmol/8×108之间的患者中有6例发生ATI(18.8%),而22例6-TGN水平不在此范围内的患者中有14例(63.6%),46例单药治疗患者中有32例(69.6%)(p=0.001)。6-TGN在235 - 450 pmol/8×108之间的患者与6-TGN不在此范围内的患者相比,ATI预防的OR (95% CI)为7.6 (2.2,26.3)(p=0.001),与单药治疗相比为9.9 (3.3,29.4)(p=0.001)。结论:235 ~ 450 pmol/8×108红细胞6-TGN水平可抑制ATI的产生。这支持治疗药物监测,以帮助指导治疗,并最大限度地提高IBD患者联合治疗的有益效果。
{"title":"Association between 6-thioguanine nucleotide levels and preventing production of antibodies to infliximab in patients with inflammatory bowel disease.","authors":"Jennifer Phillips, Sam Leary, Jonathan Tyrrell-Price","doi":"10.1136/bmjgast-2023-001149","DOIUrl":"10.1136/bmjgast-2023-001149","url":null,"abstract":"<p><strong>Objective: </strong>Combination therapy with infliximab and a thiopurine has been shown to be more effective than monotherapy in patients with inflammatory bowel disease (IBD). The therapeutic efficacy of thiopurines is correlated with 6-thioguanine (6-TGN) levels between 235 and 450 pmol/8×10<sup>8</sup> erythrocytes. The primary aim of the study was to investigate the association between 6-TGN levels and inhibition prevention of the production of antibodies to infliximab (ATI).</p><p><strong>Design: </strong>We performed a retrospective review of the medical records of patients being treated with infliximab for IBD at University Hospitals Bristol NHS Foundation Trust. Demographic and biochemical data were extracted, alongside thiopurine metabolite levels, trough levels of infliximab and the presence of ATI. χ<sup>2</sup> tests were used to investigate the association between 6-TGN levels and prevention of ATI. Logistic regression was used to compare the odds of prevented ATI between those with a 6-TGN level between 235 and 450 pmol/8×10<sup>8</sup> erythrocytes, those with a 6-TGN level outside of this range, and the baseline group who were on infliximab monotherapy.</p><p><strong>Results: </strong>Data were extracted for 100 patients. Six of 32 patients with a 6-TGN level between 235 and 450 pmol/8×10<sup>8</sup> erythrocytes developed ATI (18.8%) compared with 14 out of 22 (63.6%) patients with a 6-TGN outside of this range and 32 out of 46 (69.6%) patients on monotherapy (p=0.001). The OR (95% CI) for prevented ATI in those with a 6-TGN between 235 and 450 pmol/8×10<sup>8</sup> erythrocytes compared with a 6-TGN outside of this range was 7.6 (2.2, 26.3) (p=0.001) and compared with monotherapy was 9.9 (3.3, 29.4) (p=0.001).</p><p><strong>Conclusion: </strong>6-TGN levels between 235 and 450 pmol/8×10<sup>8</sup> erythrocytes prevented production of ATI. This supports therapeutic drug monitoring to help guide treatment and maximise the beneficial effects of combination therapy for patients with IBD.</p>","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":"10 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/34/3e/bmjgast-2023-001149.PMC10277032.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9661675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Planning management for complex colorectal polyps: a qualitative assessment of factors influencing decision-making among colonoscopists. 复杂结肠息肉的计划管理:影响结肠镜医师决策因素的定性评估。
IF 3.1 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-05-01 DOI: 10.1136/bmjgast-2022-001097
Jody Parker, Lenira Semedo, Lavanya Shenbagaraj, Jared Torkington, Sunil Dolwani

Objective: Endoscopic therapy is the recommended primary treatment for most complex colorectal polyps, but high colonic resection rates are reported. The aim of this qualitative study was to understand and compare between specialities, the clinical and non-clinical factors influencing decision making when planning management.

Design: Semi-structured interviews were performed among colonoscopists across the UK. Interviews were conducted virtually and transcribed verbatim. Complex polyps were defined as lesions requiring further management planning rather than those treatable at the time of endoscopy. A thematic analysis was performed. Findings were coded to identify themes and reported narratively.

Results: Twenty colonoscopists were interviewed. Four major themes were identified including gathering information regarding the patient and their polyp, aids to decision making, barriers in achieving optimal management and improving services. Participants advocated endoscopic management where possible. Factors such as younger age, suspicion of malignancy, right colon or difficult polyp location lead towards surgical intervention and were similar between surgical and medical specialties. Availability of expertise, timely endoscopy and challenges in referral pathways were reported barriers to optimal management. Experiences of team decision-making strategies were positive and advocated in improving complex polyp management. Recommendations based on these findings to improve complex polyp management are provided.

Conclusion: The increasing recognition of complex colorectal polyps requires consistency in decision making and access to a full range of treatment options. Colonoscopists advocated the availability of clinical expertise, timely treatment and education in avoiding surgical intervention and providing good patient outcomes. Team decision-making strategies for complex polyps may provide an opportunity to coordinate and improve these issues.

目的:内镜下治疗是大多数复杂结肠息肉的首选治疗方法,但据报道结肠切除率很高。本质性研究的目的是了解和比较专科、临床和非临床因素对计划管理决策的影响。设计:在英国结肠镜医师中进行半结构化访谈。采访以虚拟方式进行,并逐字记录。复杂息肉被定义为需要进一步管理计划的病变,而不是在内窥镜检查时可治疗的病变。进行了专题分析。研究结果被编码以确定主题,并以叙述的方式进行报告。结果:对20名结肠镜医师进行了访谈。确定了四个主要主题,包括收集有关患者及其息肉的信息,帮助决策,实现最佳管理的障碍和改善服务。与会者主张尽可能进行内窥镜治疗。年龄小、怀疑恶性肿瘤、右结肠或息肉定位困难等因素导致手术干预,在外科和内科专业之间相似。专家的可用性,及时的内窥镜检查和转诊途径的挑战被报道为最佳管理的障碍。团队决策策略在改善复杂息肉管理方面的经验是积极的和提倡的。基于这些发现提出了改善复杂息肉治疗的建议。结论:对复杂结直肠息肉的认识不断提高,需要决策的一致性和获得全面的治疗方案。结肠镜医师提倡临床专业知识的可用性,及时治疗和避免手术干预的教育,并提供良好的患者结果。复杂息肉的团队决策策略可能提供一个协调和改善这些问题的机会。
{"title":"Planning management for complex colorectal polyps: a qualitative assessment of factors influencing decision-making among colonoscopists.","authors":"Jody Parker,&nbsp;Lenira Semedo,&nbsp;Lavanya Shenbagaraj,&nbsp;Jared Torkington,&nbsp;Sunil Dolwani","doi":"10.1136/bmjgast-2022-001097","DOIUrl":"https://doi.org/10.1136/bmjgast-2022-001097","url":null,"abstract":"<p><strong>Objective: </strong>Endoscopic therapy is the recommended primary treatment for most complex colorectal polyps, but high colonic resection rates are reported. The aim of this qualitative study was to understand and compare between specialities, the clinical and non-clinical factors influencing decision making when planning management.</p><p><strong>Design: </strong>Semi-structured interviews were performed among colonoscopists across the UK. Interviews were conducted virtually and transcribed verbatim. Complex polyps were defined as lesions requiring further management planning rather than those treatable at the time of endoscopy. A thematic analysis was performed. Findings were coded to identify themes and reported narratively.</p><p><strong>Results: </strong>Twenty colonoscopists were interviewed. Four major themes were identified including gathering information regarding the patient and their polyp, aids to decision making, barriers in achieving optimal management and improving services. Participants advocated endoscopic management where possible. Factors such as younger age, suspicion of malignancy, right colon or difficult polyp location lead towards surgical intervention and were similar between surgical and medical specialties. Availability of expertise, timely endoscopy and challenges in referral pathways were reported barriers to optimal management. Experiences of team decision-making strategies were positive and advocated in improving complex polyp management. Recommendations based on these findings to improve complex polyp management are provided.</p><p><strong>Conclusion: </strong>The increasing recognition of complex colorectal polyps requires consistency in decision making and access to a full range of treatment options. Colonoscopists advocated the availability of clinical expertise, timely treatment and education in avoiding surgical intervention and providing good patient outcomes. Team decision-making strategies for complex polyps may provide an opportunity to coordinate and improve these issues.</p>","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":"10 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3c/2a/bmjgast-2022-001097.PMC10230910.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9745075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Obstacles to the deceased donor transplantation in Pakistan. 巴基斯坦死亡供体移植的障碍。
IF 3.1 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-05-01 DOI: 10.1136/bmjgast-2022-001101
Kaleem Ullah, Abdul Wahab Dogar, Sidhant Ochani, Azam Shoaib, Hussain Haider Shah, Mohammad Ebad Ur Rehman

Introduction: Transplantation in many Asian countries is moulded by socioeconomic, religious, cultural and health indicators. In most Asian countries, the living-related donation is the common most organ donation. Due to the limited deceased organ donation, live donor programmes flourished in many Asian countries. Another apparent reason for this tremendous growth of living-related programmes in Asian countries is their larger serving population. Several centres from Asia, including Pakistan and India from Southeast Asia and Egypt in Middle East Asia, on the one hand, have recently emerged as leading living donor transplant programmes. On the other hand, a few Asian countries, including Iran and China, have established some of the world's largest deceased donor programmes.

Discussion: In Pakistan, thousands of patients die from end-stage organ failure annually, seeking organ transplants for survival. The exact statics are not available, but over 50 000 people are estimated to die each year as a result of end-stage organ failure without getting a transplant, about 15 000-18 000 from kidney failure, and 10 000 from liver failure and the National Centre for Health Statistics labelled organ failure as a leading cause of death. Despite all these efforts, the knowledge of organ donation among Pakistani people was determined to be around 60%. In Pakistan, the lack of deceased organ donation programmes and the unwillingness of people to deceased organ donation contributes to an increased demand for living organ donation and patients continue to rely on living donors. We discuss various obstacles to deceased organ donation comprising various challenges that form a unique combination, including religious, economic, social, demographic and political factors.Conclusion: Every single effort should be made to initiate and establish multiple deceased donor programmes in Pakistan. Developing the deceased donor programmes in the country will be vital to counter the countrywide increasing organ shortage. The mainstay transplant activities like organ procurement and distribution systems need to be adequately developed. It will help achieve national self-sufficiency and decrease living donors' burden. With education, the behaviour of healthcare professionals and common people can be changed and a positive attitude toward deceased organ donation can be obtained. As healthcare professionals, we should come forward and take responsibility by enrolling ourselves in deceased donors' registration. Public awareness, medical community interest and government support are essential in initiating and establishing deceased donor programmes in Pakistan.

导言:移植在许多亚洲国家是由社会经济、宗教、文化和健康指标决定的。在大多数亚洲国家,亲属捐赠是最常见的器官捐赠。由于死者器官捐献有限,活体捐献计划在许多亚洲国家蓬勃发展。亚洲国家与生活有关的方案大幅增长的另一个明显原因是它们的服务人口较多。亚洲的几个中心,包括东南亚的巴基斯坦和印度以及中东的埃及,最近已成为主要的活体供体移植方案。另一方面,包括伊朗和中国在内的一些亚洲国家,已经建立了一些世界上最大的遗体捐赠计划。讨论:在巴基斯坦,每年有成千上万的患者死于终末期器官衰竭,寻求器官移植来生存。虽然没有确切的统计数据,但估计每年有5万多人死于未接受移植的终末期器官衰竭,约1.5万至1.8万人死于肾衰竭,1万人死于肝功能衰竭,国家卫生统计中心将器官衰竭列为死亡的主要原因。尽管做出了这些努力,但巴基斯坦人对器官捐赠的了解程度确定在60%左右。在巴基斯坦,由于缺乏死者器官捐赠规划和人们不愿意捐献死者器官,导致对活体器官捐赠的需求增加,患者继续依赖活体捐赠者。我们讨论了死者器官捐赠的各种障碍,包括形成独特组合的各种挑战,包括宗教,经济,社会,人口和政治因素。结论:应尽一切努力在巴基斯坦发起和建立多个已故捐助者方案。在该国制定死者捐献方案对于解决全国范围内日益严重的器官短缺问题至关重要。器官采购和分配系统等主要移植活动需要得到充分发展。它将有助于实现国家自给自足并减轻在世捐助者的负担。通过教育,可以改变医护人员和普通民众的行为,使他们对捐献死者器官持积极态度。作为医护专业人士,我们应该挺身而出,承担起责任,参与死者捐献登记。在巴基斯坦,公众意识、医学界的兴趣和政府的支持对于启动和建立已故捐赠者方案至关重要。
{"title":"Obstacles to the deceased donor transplantation in Pakistan.","authors":"Kaleem Ullah,&nbsp;Abdul Wahab Dogar,&nbsp;Sidhant Ochani,&nbsp;Azam Shoaib,&nbsp;Hussain Haider Shah,&nbsp;Mohammad Ebad Ur Rehman","doi":"10.1136/bmjgast-2022-001101","DOIUrl":"https://doi.org/10.1136/bmjgast-2022-001101","url":null,"abstract":"<p><strong>Introduction: </strong>Transplantation in many Asian countries is moulded by socioeconomic, religious, cultural and health indicators. In most Asian countries, the living-related donation is the common most organ donation. Due to the limited deceased organ donation, live donor programmes flourished in many Asian countries. Another apparent reason for this tremendous growth of living-related programmes in Asian countries is their larger serving population. Several centres from Asia, including Pakistan and India from Southeast Asia and Egypt in Middle East Asia, on the one hand, have recently emerged as leading living donor transplant programmes. On the other hand, a few Asian countries, including Iran and China, have established some of the world's largest deceased donor programmes.</p><p><strong>Discussion: </strong>In Pakistan, thousands of patients die from end-stage organ failure annually, seeking organ transplants for survival. The exact statics are not available, but over 50 000 people are estimated to die each year as a result of end-stage organ failure without getting a transplant, about 15 000-18 000 from kidney failure, and 10 000 from liver failure and the National Centre for Health Statistics labelled organ failure as a leading cause of death. Despite all these efforts, the knowledge of organ donation among Pakistani people was determined to be around 60%. In Pakistan, the lack of deceased organ donation programmes and the unwillingness of people to deceased organ donation contributes to an increased demand for living organ donation and patients continue to rely on living donors. We discuss various obstacles to deceased organ donation comprising various challenges that form a unique combination, including religious, economic, social, demographic and political factors.<b>Conclusion:</b> Every single effort should be made to initiate and establish multiple deceased donor programmes in Pakistan. Developing the deceased donor programmes in the country will be vital to counter the countrywide increasing organ shortage. The mainstay transplant activities like organ procurement and distribution systems need to be adequately developed. It will help achieve national self-sufficiency and decrease living donors' burden. With education, the behaviour of healthcare professionals and common people can be changed and a positive attitude toward deceased organ donation can be obtained. As healthcare professionals, we should come forward and take responsibility by enrolling ourselves in deceased donors' registration. Public awareness, medical community interest and government support are essential in initiating and establishing deceased donor programmes in Pakistan.</p>","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":"10 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9d/01/bmjgast-2022-001101.PMC10230924.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9682787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
BMJ Open Gastroenterology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1